Getting the science right
The ‘no pain, no gain’ mantra seems to be finally putting the $25 billion AstraZeneca on the road to recovery, as it continues to…
Author
New strategies for growth
After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of…
Digital India: A new game needs new rules
With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology
BI’s afatinib LUX-Lung 8 trial data released at ASCO 2015
Patients from 23 countries, including India, participated in the trial, which is reportedly the first prospective trial to…
Lee Pharma revives the CL debate
With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to…
TRIPs-ing time again
When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug…
Data integrity … dil se
Two reports, released in early June, have both good news and bad news for the pharma industry in India
2015 USTR Special 301 Report Reactions and the way forward
In the aftermath of this year’s USTR Special 301 Report, which retained India on the Priority Watch List, industry leaders comment…
Wish list for PM Modi’s second year
Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the pharma sector as well
Now that the…
When patience is not a virtue
India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year, the reaction from India’s…